These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 23471131)

  • 21. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial.
    Sigrist M; Tang M; Beaulieu M; Espino-Hernandez G; Er L; Djurdjev O; Levin A
    Nephrol Dial Transplant; 2013 Jan; 28(1):161-9. PubMed ID: 23024219
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
    Gonzalez-Parra E; Gonzalez-Casaus ML; Galán A; Martinez-Calero A; Navas V; Rodriguez M; Ortiz A
    Nephrol Dial Transplant; 2011 Aug; 26(8):2567-71. PubMed ID: 21436379
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
    Toida T; Fukudome K; Fujimoto S; Yamada K; Sato Y; Chiyotanda S; Kitamura K
    Clin Nephrol; 2012 Sep; 78(3):216-23. PubMed ID: 22874110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease.
    Houston J; Smith K; Isakova T; Sowden N; Wolf M; Gutiérrez OM
    J Ren Nutr; 2013 Jan; 23(1):12-20. PubMed ID: 22406119
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease.
    Zhang S; Gillihan R; He N; Fields T; Liu S; Green T; Stubbs JR
    Kidney Int; 2013 Oct; 84(4):713-21. PubMed ID: 23698235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Yang JY; Chen HY; Pai MF; Lin WY; Hung KY; Chu FY; Tsai SM; Chien KL
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1475-1483. PubMed ID: 31519550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
    Noto L
    J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
    Palmer SC; Gardner S; Tonelli M; Mavridis D; Johnson DW; Craig JC; French R; Ruospo M; Strippoli GF
    Am J Kidney Dis; 2016 Nov; 68(5):691-702. PubMed ID: 27461851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
    Lioufas N; Toussaint ND; Pedagogos E; Elder G; Badve SV; Pascoe E; Valks A; Hawley C;
    BMJ Open; 2019 Feb; 9(2):e024382. PubMed ID: 30796122
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute effects of very-low-protein diet on FGF23 levels: a randomized study.
    Di Iorio B; Di Micco L; Torraca S; Sirico ML; Russo L; Pota A; Mirenghi F; Russo D
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):581-7. PubMed ID: 22362063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
    Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
    J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study.
    Prats M; Font R; García C; Cabré C; Jariod M; Vea AM
    BMC Nephrol; 2013 Jul; 14():167. PubMed ID: 23902731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.
    de Borst MH; Baia LC; Hoogeveen EK; Giltay EJ; Navis G; Bakker SJL; Geleijnse JM; Kromhout D; Soedamah-Muthu SS
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29137111
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.
    Ito E; Inaguma D; Koide S; Takahashi K; Hayashi H; Hasegawa M; Yuzawa Y
    Clin Exp Nephrol; 2018 Dec; 22(6):1309-1314. PubMed ID: 29748907
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and baseline characteristics of the LANDMARK study.
    Ogata H; Fukagawa M; Hirakata H; Kaneda H; Kagimura T; Akizawa T;
    Clin Exp Nephrol; 2017 Jun; 21(3):531-537. PubMed ID: 27405619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperphosphatemia and phosphate binders: effectiveness and safety.
    Kalaitzidis RG; Elisaf MS
    Curr Med Res Opin; 2014 Jan; 30(1):109-12. PubMed ID: 24007207
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I; Haffner D; Leifheit-Nestler M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.